Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS 19 Return-on-Tangible-Equity is 21.75% as of Mar. 2026, which is 78% below its 10-year median of 98.84. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 901 Drug Manufacturers companies, Curis Lifesciences ranks better than 80.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Curis Lifesciences's annualized net income for the quarter that ended in Mar. 2026 was ₹69.2 Mil. Curis Lifesciences's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹317.9 Mil. Therefore, Curis Lifesciences's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.75%.
The historical rank and industry rank for Curis Lifesciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:CURIS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 21.75 Med: 98.84 Max: 186.45
Current: 21.75
During the past 4 years, Curis Lifesciences's highest Return-on-Tangible-Equity was 186.45%. The lowest was 21.75%. And the median was 98.84%.
NSE:CURIS's Return-on-Tangible-Equity is ranked better than 80.58% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs NSE:CURIS: 21.75
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Curis Lifesciences Return-on-Tangible-Equity Related Terms
Curis Lifesciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CURIS vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.75% mean?
Curis Lifesciences (NSE:CURIS) has a Return-on-Tangible-Equity of 21.75% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Curis Lifesciences and its competitors. This is 78% below median its historical median of 98.84. Over the past decade, Curis Lifesciences' Return-on-Tangible-Equity has ranged from 21.75 to 186.45. According to the industry distribution chart, Curis Lifesciences ranks #175 out of 901 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Curis Lifesciences' Return-on-Tangible-Equity too high?
Curis Lifesciences' current Return-on-Tangible-Equity of 21.75% is 78% below median its 10-year median of 98.84. Over the past 10 years, this metric has ranged from a low of 21.75 to a high of 186.45. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.89. Curis Lifesciences' value of 21.75% is 175.7% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #175 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #175 out of 901 companies for Return-on-Tangible-Equity. This places Curis Lifesciences in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.89. Curis Lifesciences' value of 21.75% is 175.7% above this benchmark. Historically, Curis Lifesciences' own Return-on-Tangible-Equity has ranged from 21.75 to 186.45 over the past decade. While the company's 10-year median is 98.84 vs. the industry median of 7.89, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Return-on-Tangible-Equity of 21.75% is 175.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Return-on-Tangible-Equity is 21.75%, which is 78% below median its own 10-year median of 98.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Return-on-Tangible-Equity of 21.75%. The current Return-on-Tangible-Equity is 21.75%, which is 78% below median its 10-year median of 98.84 and 175.7% above the Drug Manufacturers industry median of 7.89. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Return-on-Tangible-Equity is 21.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
